Alfaro-Rodríguez A, Vargas-Sánchez J, Bandala C, Uribe-Escamilla R

Idioma: Español
Referencias bibliográficas: 35
Paginas: 345-350
Archivo PDF: 149.07 Kb.

RESUMEN

Introducción. Varios autores han reportado diferentes resultados en estudios de investigación sobre el impacto de la carbamazepina (CBZ) sobre las respuestas de la vía auditiva. Objectivo. Evaluar los cambios en la vía auditiva por medio de potenciales evocados auditivos de tallo cerebral (PEATC) a diferentes intensidades de sonido administrando una dosis de CBZ de 30 mg/kg, en ratas Wistar. Material y métodos. Veinte ratas Wistar adultas, machos (peso promedio, 280-300 g) fueron usadas como sujetos de estudio. Los PEATC se realizaron con estímulos de 30, 50 y 70 dB nHL de intensidad, se obtuvieron los PEATC con y sin tratamiento de carbamazepina. Resultados. Los picos de las latencias de los PEATC entre los grupos fueron diferentes. En el grupo con CBZ se encontró prolongación en las latencias, al analizar los intervalos inter-onda entre los grupos, se encontraron diferencias significativas en los intervalos III-V y I-V a la intensidad de 70 dB nHL. Conclusiones. Los resultados sugieren que la CBZ modifica los intervalos inter-onda de los PEATC a una intensidad de 70 dB, además de prolongación de las latencias en general. CBZ produce cambios en la sensibilidad auditiva con una simple dosis no tóxica. Probablemente CBZ causa cambios en la composición del líquido endolinfático del oído interno de la rata, provocando que las latencias se vean afectadas, pero esto requiere futuros estudios.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Luo JJ, Khurana DS, Kothare SV. Brainstem auditory evoked potentials and middle latency auditory evoked potentials in young children. J Clin Neurosci 2013; 20: 383-8.

2. Burkard RF, Don M. The auditory brainstem response. In: Burkard RF, Don M, Eggermont JJ (eds.). Auditory evoked potentials. Basic principles and clinical application. Philadelphia: Lippincott Williams & Wilkins; 2007, p. 229-50.

3. Kashihara K, Imai K, Shiro Y, Shohmori T. Reversible pitch perception deficit due to carbamazepine. Int Med 1998; 37: 774-5.

4. Kobayashi T, Nisijima K, Ehara Y, et al. Pitch perception shift: A rare side-effect of carbamazepine. Psychiatry Clin Neurosci 2001; 55: 415-7.

5. Yoshikawa H, Abe T. Carbamazepine-induced abnormal pitch perception. Brain Dev 2003; 25: 127-9.

6. Marciani MG, Spannedda F, Mattia D. Neurophysiologic and neuropsychologic profiles of lamotrigine in epilepsy. Clin Neuropharmacol 1999; 22: 159-63.

7. Mervaala E, Partanen J, Nousianinen U, Sivenius J, Riekkinen P. Electrophysiologic effects of gamma-vinyl-GABA and carbamazepine. Epilepsia 1989; 30: 189-93.

8. Wu X, Xiao CH. Quantitative pharmaco-EEG of carbamazepine in volunteers and epileptics. Clin Electroencephalogr 1996; 27: 40-5.

9. Mervaala E, Keränen T, Tiihonen P, Riekkinen P. The effects of carbamazepine and sodium valproate on SEPs and BAEPs. Electroencephalogr Clin Neurophysiol 1987; 68: 475-8.

10. Krause KH, Berlit P. Nerve conduction velocity in patients under long term treatment with antiepileptic drugs. Electromyogr Clin Neurophysiol 1990; 30: 61-4.

11. Mecarelli O, Rinalduzzi S, Accornero N. Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers. Clin Neuropharmacol 2001; 24: 23-6.

12. Verotti A, Trotta D, Cutarella R, Pascarella R, Morgese G, Chiarelli F. Effects of antiepileptic drugs on evoked potentials in epileptic children. Pediatr Neurol 2000; 23: 397-402.

13. Zgorzalewicz M. Bimodal evoked potentials during longterm therapy with conventional or slow release preparations of carbamazepine and valproic acid in children and adolescents with epilepsy. Neurol Neurochir Pol 2000; (Suppl. 1): 119-28.

14. Faingold CL, Hoffmann WE, Stittsworth JD Jr. Pentylenetetrazol- induced enhancement of reticular formation auditory evoked potentials and acoustic startle responses in the cat. Neuropharmacology 1981; 20: 787-9.

15. Hirose G, Kitagawa Y, Chujo T, Oda R, Kataoka S, Takado M. Acute effects of phenytoin on brainstem auditory evoked potentials: clinical and experimental study. Neurology 1986; 36: 1521-4.

16. Hirose G, Chujo T, Kataoka S, Kawada J, Yoshioka A. Acute effects of anticonvulsants on brain-stem auditory evoked potentials in rats. Electroencephalogr Clin Neurophysiol 1990; 75: 543-7.

17. Alfaro-Rodríguez A, González-Piña R, Arch-Tirado E, Carrasco- Portugal M, Pérez-Guillé B, Soriano-Rosales RE, et al. Neuro- protective effects of carbamazepine on sleep patterns and head and body shakes in kainic acid-treated rats. Chem Biol Interact 2009; 180: 376-82.

18. Sitges M, Nekrassov V. Acute and chronic effects of carbamazepine, phenytoin, valproate and vinpocetine on BAEP parameters and threshold in the guinea pig. Clin Neurophysiol 2007; 118: 420-6.

19. Riazi K, Honar H, Homayoun H, Rashidi N, Dehghani M, Sadeghipour H, Gaskari SA, et al. Sex and estrus cycle differences in the modulatory effects of morphine on seizure susceptibility in mice. Epilepsia 2004; 45: 1035-42.

20. Kirk RF. Experimental design: Procedures for the behavioral sciences. 2nd Ed. Brooks/Cole; 1982.

21. Castro L. Diseño experimental sin estadística. Usos y restricciones en su aplicación a las ciencias de la conducta. 2a Ed. México: Trillas; 1992.

22. Chaudhary Shatdal, Karki Prahlad, Bajaj Bhupender Kumar. Evaluation of Brainstem auditory evoked potential in diabe tics. Journal of Universal College of Medical Sciences 2013; 1(2): 8-12.

23. Wakamoto H, Kume A, Nakano N. Elevated pitch perception owing to carbamazepine-activating effect on the peripheral auditory system: auditory brainstem response study. J Child Neurol 2004; 19: 453-5.

24. Rysz A, Gajdowski K. Effect of phenytoin and carbamazepine on evoked potentials in patients with newly dignosed epilepsy. Part II. Brainstem auditory evoked potentials. Neurol Neurochir Pol 1996; 6: 971-9.

25. Van der Meyden CH, Bartel RP, De Sommers K, et al. Effect of acute doses of controlled-release carbamazepine on clinical, psychomotor, electrophysiological, and cognitive parameters of brain function. Epilepsia 1992; 33: 335-42.

26. Mervaala E, Keranen T, Tiihonen P, Riekkinen P. The effects of carbamazepine and sodium valproate on SEPs and BAEPs. Electroencephalogr Clin Neurophysiol 1987; 68: 475-8.

27. Fromm GH. Effects of different classes of antiepileptic drugs on brain-stem pathways. Federation Proc 1985; 44: 2432-5.

28. Yamazaki M, Kim KX, Marcus DC. Sodium selectivity of Reissner’s membrane epithelial cells. BMC Physiol 2011; 1: 11-14.

29. Wangemann P, Schacht J. Homeostatic mechanisms in the cochlea. In Dallos P, Popper AN, Fay RR (eds.). The Cochlea. Springer-Verlag, New York; 1996, p. 130-85.

30. Gründer S, Müller A, Ruppersberg JP. Developmental and cellular expression pattern of epithelial sodium channel alpha, beta and gamma subunits in the inner ear of the rat. Eur J Neurosci 2001; 13: 641-8.

31. Marcus DC, Wangemann P. Inner ear fluid homeostasis. In: Fuchs PA (ed.). The Oxford Handbook of Auditory Science: The Ear. Oxford: Oxford University Press; 2010: 213-30.

32. Marcus DC, Wangemann P. Cochlear and Vestibular Function and Dysfunction. In: Alvarez-Leefmans FJ, Delpire E. Physiology and Pathology of Chloride Transporters and Channels in the Nervous System-From molecules to diseases. New York: Elsevier; 2009, p. 425-37.

33. Kim SH, Marcus DC. Regulation of Sodium Transport in the Inner Ear. Hear Res 2011; 280(1-2): 21-9.

34. De la Cruz M, Bance M. Carbamazepine induced sensorineural hearing loss. Arch Otolaryngol Head and Neck Surgery 1999; 125: 225-7.

35. Eggermont JJ. Correlated neural activity as the driving force for functional changes in auditory cortex. Hearing Research 2007; 229: 69-80.